GlaxoSmithKline Augments Antibacterial Franchise With Pliva Purchase
This article was originally published in The Pink Sheet Daily
Executive Summary
$50 mil. acquisition of the Croatian lab that gave Pfizer Zithromax could provide GSK with a successor to Augmentin.
You may also be interested in...
GSK Antibiotic Retapamulin Has September User Fee Date
GlaxoSmithKline's topical antibacterial retapamulin has a September user fee date
Pliva Divests Sanctura, Cites Lack Of Resources To Support The Incontinence Agent
The overactive bladder therapy is the first product to be divested as part of a strategic realignment under which Pliva will exit the brand business. The company says brand products are not meeting expectations, and the resources needed are higher than once expected.
Augmentin ES-600 Generics Launch
The launch of Teva's generic version of Augmentin ES-600 on Sept. 17 triggered an "authorized" generic from Ivax.